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Surfactant inhibitionThe respiratory epithelium has evolved to produce a complicated network of extracellular membranes that
are essential for breathing and, ultimately, survival. Surfactant membranes form a stable monolayer at the
air–liquid interface with bilayer structures attached to it. By reducing the surface tension at the air–liquid in-
terface, surfactant stabilizes the lung against collapse and facilitates inﬂation. The special composition of sur-
factant membranes results in the coexistence of two distinct micrometer-sized ordered/disordered phases
maintained up to physiological temperatures. Phase coexistence might facilitate monolayer folding to form
three-dimensional structures during exhalation and hence allow the ﬁlm to attain minimal surface tension.
These folded structures may act as a membrane reserve and attenuate the increase in membrane tension dur-
ing inspiration. The present review summarizes what is known of ordered/disordered lipid phase coexistence
in lung surfactant, paying attention to the possible role played by domain boundaries in the monolayer-to-
multilayer transition, and the correlations of biophysical inactivation of pulmonary surfactant with alter-
ations in phase coexistence.
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To facilitate gas exchange, the lung has the largest epithelial sur-
face area of the body in contact with the external environment. Our
current understanding of the alveolus includes (Fig. 1): type Iipalmitoylphosphatidylcholine;
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l rights reserved.epithelial cells that mediate gas exchange; type II epithelial cells
that produce and secrete lung surfactant and, in addition, have prolif-
erative and innate immune functions; endothelial cells with critical
gas exchange and metabolic functions; alveolar macrophages that co-
ordinate host defense; and interstitial ﬁbroblasts that support alveo-
lar structure through the secretion of extracellular matrix proteins
[1]. In addition, epithelial cells and alveolar macrophages are covered
by a layer of aqueous ﬂuid that contains extracellular membranes
called pulmonary surfactant (Fig. 1). Surfactant is necessary to keep
the alveolus open, thereby allowing gas exchange. Without surfactant
the alveoli collapse since the surface tension at the air–water inter-
face exerts a collapsing pressure. Thus, one of the main lung surfac-
tant functions is to form a stable lipid monolayer at the air–liquid
interface that excludes water molecules from the interface and effec-
tively lowers surface tension to almost 0 mN/m on expiration [2–6].
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Fig. 1. The alveoli are composed of a thin alveolar epithelium composed of two cell
types: thin, squamous type I cells, which cover 95% of the alveolar surface and form
the structure of the alveolar wall, and cuboidal type II cells that secrete pulmonary sur-
factant. Alveoli also contain macrophages that are involved in lung defense. The alveo-
lar epithelial cells and alveolar macrophages are covered by a layer of aqueous ﬂuid
that contains extracellular membranes called pulmonary surfactant.
SP-CSP-B
Surfactant proteins
2551C. Casals, O. Cañadas / Biochimica et Biophysica Acta 1818 (2012) 2550–2562Lung surfactant not only protects the lung against alveolar collapse
and facilitates inﬂation on inspiration, but, together with alveolar mac-
rophages, constitutes the front line of defense against inhaled patho-
gens and toxins. These two essential surfactant functions—lowering
surface tension and host defense—depend on the complexity of the
lipid and protein constituents of the surfactant system [7–10]. It is
thought that these two functions are inseparably coordinated so that
host defense mechanisms at the interface do not interfere with the
surface-active properties of the surfactant system.
Lung immaturity and surfactant deﬁciency are themain factors in the
pathogenesis of neonatal respiratory distress syndrome (RDS) [10,11]. In
addition, surfactant dysfunction, caused by inactivation of surface-active
material in the airspaces, contributes to respiratory failure in other forms
of neonatal or adult lung diseases [4,8,10–12]. Airway instillation of sur-
factant is in general use for treatment of RDS in preterm babies [11].
Animal-derived replacement surfactants consist of lipid extract prepara-
tions obtained from animal bronchoalveolar ﬂuids [11]. Unfortunately,
commercial animal-derived replacement surfactants have inferior sur-
face activity and are more susceptible to inactivation than native surfac-
tants, possibly as a consequence of their reduced SP-B/C content, the lack
of SP-A, and (with the exception of Survanta) higher fractions of unsatu-
rated phospholipid species than natural surfactant [13]. A better compre-
hension of structure–function determinants in pulmonary surfactant is
needed. This reviewwill focus on the biophysical properties of surfactant
membranes, paying attention to the importance of ordered/disordered
phase coexistence in such membranes.SP-DSP-A
Fig. 2. Three‐dimensional models of surfactant proteins. Models of the hydrophilic sur-
factant proteins SP-A and SP-D were constructed based on electron microscopy pic-
tures of these proteins and the three-dimensional structure determined for trimers of
SP-A [39] and SP-D [40] composed of C-globular and neck domains. The structural
model of SP-C is based on the conformation of the protein determined by NMR in or-
ganic solvents [27]. The structural model of SP-B is based on predictive studies of the
potential position of helical segments in the protein.2. The repertoire of surfactant lipids and proteins
Thematerial isolated from cell-free bronchoalveolar ﬂuid (BAL) con-
sists of approximately 90 wt.% lipids (mainly phospholipids, PL) and
10 wt.% proteins. Lung surfactant is isolated from BAL by differential
and density gradient centrifugation. Isolated large surfactant aggregates
(LA), which consist of large membrane structures with relatively high
density and very good surface activity, contain surfactant lipids and
apolipoproteins SP-A, SP-B, and SP-C, but not SP-D (Fig. 2). Given that
SP-D does not bind to surfactant membranes, SP-D remains in the
supernatant during fractionation by ultracentrifugation. This fractionalso contains small phospholipid vesicles, known as small surfactant
aggregates (SA), with poor surface activity, and other proteins and
peptides present in the alveolar ﬂuid.
The lipid composition of mammalian extracellular surfactant (large
aggregates) is strikingly similar to that of intracellular surfactant stored
in lamellar bodies (characteristic inclusion organelles of surfactant pro-
duced by type II cells [14]) and is remarkably similar among diverse spe-
cies. The lipids consist mainly of PL (∼90–95 wt.%) with a small amount
of neutral lipids (∼5–10 wt.%), primarily cholesterol, and α-tocopherol
that functions as anti-oxidant and could play a membrane structural
role, comparable to that of cholesterol [4,15,16]. AmongPL, phosphatidyl-
choline (PC) is the most prevalent class, accounting for ∼80 wt.% of the
total PL. Among PC molecular species, dipalmitoylphosphatidylcholine
(DPPC) (16:0/16:0-PC) is the most predominant molecular species, ac-
counting for ~55 mol% (in human [17,18], rat [19], pig, and mouse [18])
to ~40±5 mol% (in goat [20], caw [19,21], and rabbit [17]) of the total
PC. This saturated phospholipid can be packed to a very high density at
the air–water interface, providing the large reductions of surface tensions
required to stabilize the lung at the end of expiration. The remaining PC
molecular species are mainly unsaturated, containing monoenoic and
dienoic fatty acids sterifying the sn-2 position of the glycerol backbone,
e.g., palmitoyl–oleoyl phosphatidylcholine (POPC) (16:0/18:1-PC). The
acidic phospholipids, phosphatidylglycerol (PG) and phosphatidylinositol
(PI), aremainly unsaturated and account for 8–15 wt.% of the total surfac-
tant phospholipid pool. Other phospholipid classes are present at very
low levels: unsaturated phosphatidylethanolamine (PE), sphingomyelin
(SM), lyso-PC, and choline plasmalogens.
The most outstanding feature of surfactant lipid composition is not
only the high proportion of DPPC, a high Tm PL, but the fact that lung
surfactant consists of equimolar amounts of saturated and unsaturated
phospholipid species and cholesterol. Surfactant composition suggests
2552 C. Casals, O. Cañadas / Biochimica et Biophysica Acta 1818 (2012) 2550–2562that ordered/disordered domains coexist in surfactant membranes, as
has been demonstrated (see Section 4.2) thanks to the methodological
development of imaging techniques that allow greater resolution.
In addition to the lipid component, there are three surfactant apo-
lipoproteins associated with surfactant membranes. SP-B is a small
hydrophobic protein that is essential for lung function and pulmonary
homeostasis after birth. SP-B constitutes 0.7% of the total mass of iso-
lated surfactant [22]. Genetic absence of SP-B in both humans and
mice results in a lack of alveolar expansion and a lethal failure of pul-
monary function [8,10]. In contrast, genetic absence of SP-C, another
small hydrophobic protein that constitutes 0.5 wt.% [22], results in
normal expansion of alveoli and pulmonary function since SP-B is suf-
ﬁcient for surfactant function in vivo [8,10]. However, SP-C seems to
play an important role in lung innate host defense since the lack of
SP-C in SFTPC−/−mice increases markers of macrophage alternative
activation associated with diminished pathogen response and ad-
vancing pulmonary ﬁbrosis [23,24]. In addition, mutations in genes
encoding SP-C (SFTPC) have been linked to familial interstitial lung
disease [8,25]. A recent study also reported an association between
two heterozygous mutations in the SFTPA2 gene and familial pulmo-
nary ﬁbrosis [26]. These results suggest that the mutations caused
misfolding and trapping of human SP-A2 in the endoplasmic reticu-
lum that could lead to loss of misfolded SP-A2 in the airspaces. It
seems that, like SP-C, SP-A mutations have more severe consequences
than inactivated expression of SP-A gene.
Fig. 2 illustrates three-dimensional models of SP-B and SP-C. Mature
SP-C is a very small hydrophobic peptide of thirty-ﬁve amino acids. It is
one of themost hydrophobic peptides known. Its structure is character-
ized by a hydrophobic α-helix composed essentially of valine residues
and a positively charged N-terminal segment with two palmitoylated
cysteines. Its three-dimensional structure has been determined by
NMR in chloroform/methanol solutions [27], consisting of a very regular
and rigid α-helix covering approximately two thirds of the sequence
and an unstructured N-terminal segment containing prolines and the
palmitoylated cysteines. In membranes, the helical segment of SP-C
adopts a transmembrane orientation [28]. SP-C α-helix is stable within
a lipid membrane in the ﬂuid state but is unstable in aqueous organic
solvent where it is transformed into insoluble β-sheet aggregates,
which lead to amyloid ﬁbrils [29]. With respect to SP-B, unfortunately,
the three-dimensional structure of the full-length protein is not
known, but high-resolution structures of synthetic protein fragments
(e.g., N-terminal 1–25 [30] or 34-residue mini-B [31]) are available.
Analysis of the sequence of SP-B reveals that this protein belongs to
the family of the saposin-like proteins. SP-B structure might have a
characteristic saposin fold with four α-helices connected by unstruc-
tured loops and linked by three intramolecular disulﬁde bridges
[32,33]. Unlike saposin-like proteins, SP-B is a monotopical integral
membrane protein. It is thought that SP-B is inserted in bilayers or
monolayers with the main axis of its amphipathic helical segments
aligned parallel to the plane of phospholipid layers [34,35]. Although
it has been reported that both hydrophobic proteins SP-B and SP-C
alter lipid packing in surfactant membranes and enhance the surface
tension‐lowering activity of the lipids [2,10,22], recent studies indicate
that SP-B is fundamental for promoting low minimum surface tensions
and stability, whereas the presence of SP-C alone may actually have
negative inﬂuence on both parameters [36]. However, SP-C seems to
play an important role in lung innate host defense [23,24].
Fig. 2 also shows three‐dimensional models of SP-A and SP-D.
These proteins are structurally characterized by an N-terminal
collagen-like domain connected by a neck domain with globular
C-terminal domains. The C-terminal domain includes a C-type
carbohydrate recognition domain (CRD) [7,37]. These proteins are
assembled in multiples of three subunits due to their collagen do-
main [37,38]. Supratrimeric assembly can have a cruciform type
(SP-D) or bouquet type (SP-A). The three-dimensional structures
of human SP-A and SP-D trimers composed of C-terminal andneck domains have been determined [39,40]. SP-A comprises
approximately 3–5% of the total mass of surfactant and is mainly
associated with surfactant membranes [2,41]. In contrast, SP-D
constitutes about 0.5 wt.% and is not associated with lipids [2]. SP-A's
ability to bind to surfactant membranes improves the adsorption and
spreading of surfactant membranes onto an air–liquid interface [41],
protects surfactant biophysical activity from the inhibitory action of
serum proteins [4], and allows SP-A to position and concentrate togeth-
er with surfactant membranes at the front lines of defense against in-
haled toxins or pathogens [9,37,42].
3. Extracellular surfactant membrane polymorphism
After surfactant secretion by epithelial type II cells [43], morpho-
logical transformations take place in the alveolar ﬂuid (Fig. 3). The se-
creted, tightly packed surfactant membranes rapidly transfer surface-
active material to the air–liquid interface, forming the surfactant
monolayer [44–46]. After de novo adsorption, the surfactant ﬁlm is
periodically compressed during exhalation and expanded during in-
halation. Compression involves changes in surface tension (γ) from
~23 mN/m to ~1 mN/m to prevent alveolar collapse, whereas ﬁlm ex-
pansion increases γ to a maximum of 20–25 mN/m to maintain alve-
olar stability.
Several lines of evidence indicate that mechanical properties of
surfactant ﬁlms do not depend only on the behavior of a single mono-
layer. Studies using electron microscopy [47,48], atomic force micros-
copy (AFM) [49,50], neutron reﬂection [51], and captive bubble
tensiometry [48,52] indicate that the interfacial ﬁlm is thicker than
a single monolayer. Thus the surface ﬁlm consists of a surface mono-
layer plus one or more lipid bilayers, closely and apparently function-
ally associated with the interfacial monolayer. The cohesivity of these
layers also contributes to sustain the low γ reached at the end of ex-
halation. Fig. 3 illustrates pulmonary surfactant absorption to the in-
terface from secreted lamellar body-like particles and the surfactant
ﬁlm attached to a continuous network of surfactant bilayers. Multi-
layer formation could arise from the multilaminations of lamellar
bodies.
Surfactant adsorption, which means bilayer to monolayer trans-
formation, occurs in a surface tension-dependent manner. It is acti-
vated above the equilibrium surface tension (γe) (~23 mN/m) and
decreases when γ falls below γe [44,45]. Using molecular dynamics
simulations, Baoukina and Tieleman [53] show how SP-B, in a charac-
teristic saposin-fold structure that may interconvert between extend-
ed and bent conformations, might mediate the formation of a stalk-
like structure between bilayer aggregates in water and the interfacial
monolayer. A lipid ﬂow might occur between the monolayer and the
vesicle via the stalk. The direction of the ﬂow would depend on the γ
in the monolayer. Below γe (~23 mN/m), lipids are transferred from
the monolayer to the vesicle. Above the equilibrium tension, lipids
are transferred from the bilayer to the monolayer. Thus SP-Bmight fa-
cilitate lipid transfer between these structures in a surface tension-
dependent manner. These molecular dynamics simulation studies
are consistent with the reports by Chavarha et al. [54] and Farver et
al. [55] that lipid polymorphism induced by surfactant hydrophobic
proteins is required to promote adsorption.
Fig. 3 also shows highly organized structures termed “tubular my-
elin” that are formed when SP-A reacts with secreted lamellar bodies
Tubular myelin is composed of large square elongated tubes com-
prised primarily of phospholipids and proteins. In vitro reconstitution
of tubular myelin requires the presence of DPPC, PG, SP-A, SP-B, and
Ca2+ [56]. Animals with inactivated expression of SP-A lack TM [57]
and do not show any apparent respiratory dysfunction upon birth,
suggesting that TM does not have an essential role in the biophysical
function of pulmonary surfactant. The mechanism involved in the for-
mation of tubular myelin is poorly understood, as is the functional
signiﬁcance of these complex structures. Morphological studies
Monolayer Air
TM
Alveolar
fluid
SA
Alveolar 
macrophages
a b c d e
Type I peumocytesType II peumocytes
Bilayers
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Fig. 3. Extracellular surfactant membrane polymorphism. The pulmonary surfactant is synthesized by type II epithelial cells and stored as tightly packed bilayer membranes in char-
acteristic intracellular inclusions called lamellar bodies (LB) (a). After regulated secretion by exocytosis (b), LB unravel spontaneously in the alveolar ﬂuid to form multilamellar
vesicles and highly organized membranes termed tubular myelin (TM) (c). These large extracellular membranes, called large surfactant aggregates (LA), have high surface activity.
They adsorb very rapidly to the air–liquid interface. The surface ﬁlm at the alveolar air/liquid interface consists of a phospholipid monolayer with bilayer structures attached to it
(d). With surface compression and expansion cycles, small vesicles are generated (E). These vesicles are named small surfactant aggregates (SA) and have poor surface activity.
Small aggregates are taken up and degraded by alveolar macrophages and type II cells. Images shown in this ﬁgure have been reproduced with permission from (a–c) [14], (d)
[47], and (e) [58].
2553C. Casals, O. Cañadas / Biochimica et Biophysica Acta 1818 (2012) 2550–2562indicate that tubular myelin ﬁgures are in close proximity to the sur-
face layer of the alveolar ﬂuid [14]. McCormack and Whitsett [42]
suggested that tubular myelin could have a primary antimicrobial
function that would serve to collect inhaled microbes at the air–liquid
interface due to the high concentration of SP-A in these structures. It
seems possible that surfactant membranes and their apolipoproteins
simultaneously function as the primary antimicrobial defense in the
alveolar ﬂuid and as a protective layer against alveolar collapse.
With repetitive surface compression and expansion cycles, small
vesicles may be generated (SA) [58] (Fig. 3). The used and rejected sur-
factant material, with poor surface activity, is taken up continuously by
alveolar macrophages and epithelial cells in the form of small lipid ves-
icles. Type II cells recycle part of surfactant's components into lamellar
bodies. Thus alveolar cells are always in contact with surfactant mem-
branes and ingest abundant amounts of this material. The effects of
these surfactant vesicles onmacrophage activation state and on epithe-
lial cells remain unclear. The loss of surfactant from the airspaces is bal-
anced by secretion of surfactant stored in lamellar bodies. The
estimated turnover period of lung surfactant ranges from 4 to 11 h
[59]. However, the modulation of pathways involved in the balance be-
tween the intracellular storage pool and the extracellular functional
pool is unknown.
4. Phase behavior of surfactant membranes in the alveolar spaces
Surfactant membranes play a crucial role in surfactant biophysical
function. The mechanical properties of the interfacial ﬁlm, and hence
the response of surfactant membranes to the breathing cycle, are de-
termined by their physical state. Discussion of the role of surfactant
membranes on the biophysical properties of pulmonary surfactant re-
quires some knowledge about lipid phase transitions and lateral
phase segregation. Therefore, we brieﬂy review the phase behaviorof surfactant membranes (bilayers and monolayers) in comparison
with DPPC membranes, since this saturated phospholipid is the
main phospholipid component in lung surfactant and has traditional-
ly been thought responsible for lowering surface tension to near-zero
values at physiological temperatures.
4.1. Phase transitions in surfactant bilayers and the surface-active ﬁlm in
comparison with DPPC bilayers and monolayers
When DPPC molecules are dispersed in an aqueous phase, they ar-
range themselves into a closed bilayer, where the hydrophobic fatty
acid groups point toward the center of the bilayer in order to mini-
mize the unfavorable interactions between the bulk aqueous phase
and the hydrocarbon fatty acid chains. A characteristic property of
lipid membranes is their ability to undergo phase transitions induced
by temperature [60]. The DPPC bilayer can exist in either a liquid-
crystalline (Lα) or a gel (Lβ′) phase. The temperature at which this
transition takes place is known as the transition or melting tempera-
ture (Tm) [60,61]. Bilayers composed of DPPC exhibit two phase tran-
sitions induced by temperature, a pretransition from the gel (Lβ′) to
the ripple phase (Pβ′) [62], and a very sharp Pβ′/Lα transition with a
melting temperature of 41 °C (Fig. 4A). Thus DPPC bilayers in the Lβ′
phase can melt to a Lα phase by increasing temperature.
These two phases (Lβ′ and Lα) are deﬁned by the strength of the
attractive Van der Waals interactions between adjacent lipid mole-
cules [63]. The tight packing of the DPPC molecules in the gel phase,
which is due to the all-trans conﬁguration adopted by the fatty acid
acyl chains, gives rise to strong interactions between the hydrophobic
tails of the lipid molecules [63]. Consequently, lipids in Lβ′ state are
highly ordered and remain relatively immobile, exhibiting neither
lateral nor rotational mobility. In the liquid-crystalline phase, Lα, indi-
vidual DPPC molecules can have rotational and translational motions
2554 C. Casals, O. Cañadas / Biochimica et Biophysica Acta 1818 (2012) 2550–2562within each leaﬂet of the bilayer, which confers ﬂuidity to the bilayer
[64]. For this reason, the liquid-crystalline phase is also known as the
ﬂuid phase. Moreover, in Lα phase, phospholipid fatty acid chains un-
dergo trans-gauche isomerization at their C–C bonds [65], which
tends to expand the area occupied by the chains, reducing the lipid
packing and hence the strength of the interactions between adjacent
molecules. Trans-gauche isomerizations confer relative disorder to
the phospholipid acyl chains [63,65]; for this reason, the Lα ﬂuid
phase is also usually referred to as the liquid-crystalline disordered
phase (Ld).
This phase behavior is altered by the presence of cholesterol. The gen-
eral trend is that cholesterol has a ﬂuidizing effect on lipids in the gel
phase (below Tm) because the intercalation of the planar steroid mole-
cules reduces lipid packing [66]. At the same time, cholesterol has a con-
densing effect on phospholipids in the ﬂuid phase (above Tm) because
cholesterol promotes an acyl chain extension due to restriction in the
chain's ability to undergo trans-gauche isomerization [67,68]. The pres-
ence of cholesterol generates a new phase referred to as liquid‐ordered
phase (Lo) in which the orientational order of the acyl chains is similar
to that characteristic of the gel phase (Lβ’), but phospholipids in Lo
phase exhibit lateral diffusion rates and rotational motions slightlyRe
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Fig. 4. Lipid phase transitions and lateral phase separation in surfactant bilayers and monol
from healthy subjects. DPPC exhibits two transitions: a pretransition from the gel (Lβ′) to the
Human surfactant shows a broader transition with lower enthalpy. Tm, the transition midpo
pletion or upper boundary temperature. Adapted from [74]. B: GUVs of native porcine surfac
and exhibit liquid-ordered/liquid-disordered (Lo/Ld) phase coexistence at 37 °C. C: Phase b
DPPC ﬁlms at 20±1 °C. Four pressure-dependent regions are detected for the compre
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50 mN/m, monolayer-to-multilayer transition occurs and stacks of bilayers appear.
AFM pictures have been reproduced from [19] with permission.smaller but of the same order of magnitude as in Ld [67,68]. Thus Lo has
properties intermediate between the gel (Lβ’) and ﬂuid-disordered
state (Ld). Lo is an ordered phase from the point of view of the conforma-
tional structure of the lipid chains but a ﬂuid phase from the point of
view of lateral and rotational mobility of the molecules [67,69]. Thus
the ﬂuidity of the bilayers would be Lβ′bLobLd, whereas the lipid order
would be Lβ′>Lo>Ld.
Cholesterol is more soluble in the ﬂuid phase and preferentially
partitions into this phase, although, at the same time, it has a prefer-
ence for ordered acyl lipid chains [69]. The actual phase behavior of
DPPC/cholesterol mixtures depends greatly on both the temperature
and the cholesterol mol fraction. For cholesterol concentrations be-
tween 10 and 23 mol%, which correspond to the amount of cholester-
ol determined in both alveolar and lamellar body surfactant [70],
cholesterol broadens and reduces the enthalpy and temperature of
the main transition [71]. Phase diagrams indicate that for cholesterol
concentrations between 10 and 23 mol%, lateral phase separation oc-
curs and there is Lo/Ld phase coexistence at temperatures above Tm
and Lo/Lβ′ phase coexistence at temperatures below Tm [72]. Howev-
er, for cholesterol concentrations above 30 mol%, only Lo prevails over
a wide temperature range [72] and the main transition of DPPC isMONOLAYERS 
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ehavior of various clinical and natural surfactant monolayers in comparison with pure
ssion isotherms of clinical and natural surfactants: Region I. Monolayer region at
egion III. Multilayer region at π≥50 mN/m; and Region IV. Collapse region. Graph
±1 °C. At 30 mN/m, TC circular micro‐domains are observed within the LE phase. At
2555C. Casals, O. Cañadas / Biochimica et Biophysica Acta 1818 (2012) 2550–2562obliterated. Micron-scale coexisting liquid phases were initially
reported in giant unilamellar vesicles (GUVs). Ternary mixtures of a
high Tm lipid (DPPC), a low Tm lipid (Dioleoyl-PC, but not POPC),
and cholesterol (a mixture similar to surfactant membrane lipids)
form large coexisting liquid domains (Lo and Ld) over a wide range
of compositions and temperatures [73].
Fig. 4A also shows that, compared to DPPC, the thermal transition
of bilayers from human lung surfactant exhibits a broader melting
event with lower melting enthalpy (ΔH) due to the complex lipid
composition of these membranes and the presence of cholesterol
[74]. Surfactant bilayers of healthy humans exhibit a Tm of 37.2±
0.1 °C in the presence of calcium, which shifts slightly downward
(36.2±0.1 °C) in its absence [74], and a completion temperature
(TC) of ~41 °C. Over a wide temperature range (from 25 °C to the
completion temperature) surfactant membranes show micron-scale
coexisting liquid phases as described in the Section 4.2. Fig. 4B
shows a giant unilamellar vesicle formed from surfactant membranes
labeled with DiIC18 (red) and Bodipy-PC (green). The rounded green
areas in the image correspond to ﬂuid‐disordered phase, enriched in
unsaturated phospholipids. The red background corresponds to or-
dered phase, enriched in high Tm phospholipids (such as DPPC and
SM).
As stated above, pulmonary surfactant membranes arrange as a
monolayer at the air/water interface, with the lipid polar headgroups
oriented toward the aqueous phase, whereas the fatty acid chains ex-
tend into the air, avoiding contact with water. Lipid packing, and
hence the different phases in which lipids can exist in an interfacial
monolayer, is deﬁned at a given temperature by changes in compres-
sion. Thus it is possible to increase the Van der Waals interactions be-
tween lipid molecules by reducing the surface area available per lipid
molecule, giving rise to different lipid phases. Compression of surfac-
tant monolayers can be achieved in vivo during breathing cycles or in
vitro, in a surface balance, either by depositing additional lipid mole-
cules in the interface, which will increase the surface concentration,
or by moving a barrier across the surface [4,5,75]. As the amount of
lipid molecules in the interface increases, the surface tension at the
air–water interface decreases, leading to a detectable increase in sur-
face pressure. Surface pressure, π, is deﬁned as
π ¼ γ0−γ
where γ0 is the surface tension of the clean air–water interface and γ
that of the surface covered by the lipid monolayer. The dependence of
surface pressure on the surface area available per lipid molecule con-
stitutes the compression isotherm.
Fig. 4C shows the surface pressure–area (π–A) isotherms obtained
at 25 °C for monolayers of DPPC. At low compression levels,
the monolayer is in the liquid expanded (LE) phase. This phase is
characterized by low lipid packing and considerable conﬁgurational
freedom at the interface due to the presence of trans-gauche isomer-
izations [75]. Further compression of the monolayer gives rise to a
transition from LE to a highly packed state known as tilted condensed
(TC) phase where all of the acyl groups are in the extended all-trans
conﬁguration [75]. At a given temperature, the range of surface pres-
sures at which the LE/TC transition takes place depends on the nature
of the aqueous subphase. The LE/TC transition, reﬂected in the com-
pression isotherm as a plateau, takes place in the range of 7–12 mN/m
on a buffered saline subphase containing physiological amounts of
NaCl or in the range of 3–5 mN/m on a pure water subphase [76,77].
Compression of the monolayer to the TC phase can only be achieved
at temperatures below the corresponding Tm of bilayers of the same
composition. Due to the high Tm of DPPC, the acyl chains of DPPC can
be packed to a very high density at the air–water interface at physiolog-
ical temperatures, providing the large reduction of surface tensions nec-
essary to prevent alveolar collapse at end expiration [75]. A further
reduction in surface area leads to ﬁlm collapse, with irreversible lossof monolayer components. As described above for lipid bilayers, incor-
poration of cholesterol into the interfacial ﬁlmmight alter the phase be-
havior of the lipids. It has recently been reported that DPPC–cholesterol
monolayers display a phase of intermediate order between TC and LE
phases [78], whichmight be referred to as LO phase [19,79]. Cholesterol
shows a preference for the interface between TC and LE phases [78]
Compared to DPPC ﬁlms, the surface pressure–area (π–A) iso-
therms from monolayers of native lung surfactant or replacement
surfactants show a plateau region at π of 40–50 mN/m (Fig. 4C).
Zhang et al. [79] have identiﬁed four π-dependent regions for natural
and modiﬁed surfactants, based on ﬁlm structures revealed by AFM.
Region I corresponds to π in the range of 10 to 40 mN/m. Over this
wide range of π, phase coexistence between ordered and disordered
regions in the monolayers occurs, as can be observed from AFM im-
ages [79] (Fig. 4D). In rat lung surfactant the area covered by ordered
micro-domains increases with increasing surface pressure [19]. The
second region, in the surface pressure interval from 40 to 50 mN/m,
refers to the monolayer-to-multilayer transition at the equilibrium
spreading pressure, πe. The third region covers a π range from ~50
to 72 mN/m, which represents the physiologically relevant π range.
In this region, the interfacial monolayer is attached to squeezed out
bilayers. It is thought that this 3D structure composed of bilayers
functionally attached to the interfacial monolayer contributes to sus-
tain the low γ reached at the end of exhalation [53,80,81]. The fourth
region refers to the collapse of surfactant ﬁlms. The collapse pressure
(πc) is the maximum π that can be reached and sustained by a phos-
pholipid ﬁlm under lateral compression. Surfactant ﬁlms without
cholesterol appear to collapse at πc with a folding mechanism, where-
as surfactant ﬁlms with cholesterol appear to collapse with a protru-
sion mechanism, in which multilayered protrusions are uniformly
nucleated throughout the entire ﬁlm [79].
4.2. Lateral phase separation in surfactant bilayers and monolayers
The special composition of surfactant membranes, which consist
of equimolar amounts of saturated and unsaturated phospholipid
species and cholesterol, suggested the presence of ordered/disor-
dered phase coexistence under physiological conditions, based on
the information obtained in POPC/DPPC/Cholesterol model systems
[73]. In the last decade, the lateral structure of bilayers has been ex-
plored using techniques that provide spatial resolutions that range
from nano- (AFM) to micrometers (ﬂuorescence microscopy, FM).
FM and related techniques (such as ﬂuorescence lifetime imaging,
ﬂuorescence correlation spectroscopy, anisotropy imaging) provide
a lateral resolution limit of∼300 nm and require the use of ﬂuores-
cent probes. AFM detects height differences among various regions
of supported membranes (monolayers and/or bilayers) and does not
require the use of probes. To determine lateral phase segregation in
surfactant membranes, both microscopy techniques have been used.
Bernardino de la Serna et al. [82] demonstrated that GUVs composed
of native lung surfactantmembranes displaymicrometer-sized ordered/
disordered phase coexistence at physiological temperatures (Fig. 4B).
Phase coexistence depends on the lipid component because the absence
of SP-A or the extraction of thehydrophobic proteins SP-B and SP-C from
surfactant membranes does not change the characteristic phase coexis-
tence of surfactantmembranes. In native porcine surfactant phase coex-
istence occurs from 22 to 40 °C. Most of the micro-domains were
abolished at 40 °C [82,83]. Given that the melting process of human
lung surfactant terminates above 41 °C (Fig. 4A), phase coexistence
may occur at physiological temperatures (36–37 °C) and decrease in fe-
verish states.
Based on the particular round shape of the domains and the par-
tition properties of the different ﬂuorescent probes used to label sur-
factant membranes, the lateral organization of porcine surfactant
vesicles was ascribed to ﬂuid ordered/ﬂuid‐disordered-like phase
coexistence [82–84]. The nature of ordered domains was also
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methyl-β-cyclodextrin. However, given that ﬂuorescence microsco-
py distinguishes Lo and Lα phases, but not Lβ′ and Lo phases, it is pos-
sible that coexisting Lβ′, Lα, and Lo phases were present in surfactant
membranes over a range of temperatures. However, lateral diffusion
coefﬁcients, determined in NMR experiments [83], indicate that the
two types of domains segregated in surfactant bilayers have a dy-
namic character, suggesting a ﬂuid–ﬂuid (Lo/Lα) phase coexistence.
Unlike the interfacial surfactant monolayer that should be quite
rigid, surfactant membranes present in the alveolar ﬂuid seem to
be dynamic. Synthetic surfactants, which consist of combinations of
synthetic lipids and either synthetic or recombinant peptides, and
some animal-derived replacement surfactants show gel/ﬂuid phase
coexistence, instead of ﬂuid–ﬂuid phase coexistence, as a conse-
quence of the lipid composition and/or the lack [74,85] or reduced
content of cholesterol [86].
Lateral phase segregation has also been observed in interfacial ﬁlms
formed by adsorption of lamellar body-like particles secreted by rat al-
veolar type II cells [46]. Using an inverted ﬂuorescence microscope,
Ravasio and co-workers demonstrated that the ﬁlm formed by the
adsorbed material spontaneously segregates into distinct liquid-
ordered (LO), liquid-disordered (LE), and gel-like (TC) regions under
near-physiological conditions (at 37 °C and 100% rH). Themost remark-
able property ofmonolayers formed from lamellar body-like particles is
their solid-like character. The authors propose that condensation and
solidiﬁcation of the interfacial monolayer, even in the absence of
external lateral compression, could occur through an active ejection of
material into the interface. In fact, progressive adsorption of lamellar
body-like particles led to the appearance of large, protruding three-
dimensional structures, presumably accumulatingmultilayeredmateri-
al projected toward the subphase. Using different approaches, Keating
and co-workers [81] recently showed that multilayers start to form at
the edge of the solid-like (TC) domains and also in the ﬂuid-like (LE)
phase. Moreover, time-of-ﬂight secondary ion mass spectrometry
(ToF-SIMS) analysis indicated that multilayer structures are enriched
in unsaturated PLs while the saturated PLs are concentrated in the
remaining interfacial monolayer, which supports the solid-like charac-
ter of the interfacial monolayer at physiological surface pressures
(~45–72 mN/m).
Different lipid phases have also been observed in native surfactant
monolayers using different techniques: AFM [19,20,79–82,87–89],
ToF-SIMS [81,89,90], epiﬂuorescence microscopy [86,91–93], and
Brewster angle microscopy [93]. There is evidence that circularly-
shaped TC micro-domains appear at low surface pressure and increase
in area coverage with increasing π up to a surface pressure of around
35–45 mN/m. Interestingly, goat surfactant ﬁlms exhibit elongated
noodle-shaped domains, instead of circular domains, that increase in
size and length up to 40 mN/m [20]. The elongated morphology of
the domains was attributed to the low cholesterol content (0.6% by
weight) in this surfactant, whichwould decrease the line tension. In ad-
dition to TC micro-domains, TC nano-domains were observed by AFM
within the LE phase. In rat surfactant, the area covered by the nano-
domains decreased with increasing π to less than 1% of the surface
area [19]. However, bovine surfactant monolayers exhibit a decrease
in micro-domains with a corresponding increase in nano-domains
with increasing π [19,79]. A signiﬁcantly higher proportion of dis-
aturated PC was found in rat surfactant (~60 mol% of total PC species)
compared with bovine surfactant (~40 mol%) [19]. Several factors
might contribute to the micro- and nano-domain formation within
the surfactant monolayer: the speciﬁc phospholipid proﬁle (relative
percentage of saturated and unsaturated phospholipids), hydrophobic
protein content, cholesterol content, and surface pressure [19,79]. On
the other hand, coexistence of different lipid phases has also been de-
termined in monolayers from puriﬁed surfactant phospholipids, with-
out hydrophobic proteins [94–96] and in lipid mixtures containing
SP-C [97,98] and SP-B [90,99].With respect to lipid and integral membrane protein (SP-B and
SP-C) partitioning in ordered and disordered domains of surfactant
monolayers, combined ToF-SIMS and AFM studies [81,89] show that
saturated and unsaturated phospholipids segregate into different do-
mains in both bovine and rat surfactant monolayers. With respect to
hydrophobic surfactant proteins, it has been shown that SP-B and
SP-C distribute preferentially in ﬂuid regions of interfacial ﬁlms [89].
Segregation of hydrophobic proteins in the ﬂuid phase has also been
determined in surfactant-like lipid mixtures [100–104]. SP-B and
SP-C also segregate into ﬂuid regions of surfactant bilayers because
the ﬂuorescence of these proteins colocalized with the Bodipy-PC-
ﬂuid areas when ﬂuorescently labeled SP-B and SP-C were incorpo-
rated into giant unilamellar vesicles composed of surfactant lipids
[82]. With respect to SP-A, epiﬂuorescence microscopy studies show
that SP-A interacts with the ordered or gel-like regions of native sur-
factant monolayers and/or attached bilayers [92] and with TC regions
of surfactant-like lipid monolayers [105,106]. SP-A causes a reorgani-
zation or rearrangement of solid domains in the surfactant monolayer,
which is consistent with its activity to promote membrane–membrane
aggregation [37,38,41,107,108].
5. Signiﬁcance of ordered/disordered phase coexistence in surfactant
biophysical function
It is generally accepted that adsorbed surfactant material forms a sta-
ble monolayer at the air–liquid interface capable of tolerating high lateral
compression during expiration, which implies that the monolayer be-
comes enriched in solid-like phase and quite rigid. In addition, themono-
layer should be able to re-expand during inspiration (Fig. 5). The role of
lateral phase segregation in lung surfactant function is unclear, but lipid
lateral organization might be important to sustain a solid-like ﬁlm at-
tached to a continuous network of highly dynamic membranes.
Surfactant membranes connected to the surfactant monolayer are
thought to be essential for lung surfactant function [4–6,47–52,97,
103,104,109–111]. A potential mechanism for attaining high π (low γ)
during expiration can be found in themonolayer-to-multilayer transition
that represents a reversible, partial monolayer collapse occurring near πe
(i.e., 40–45mN/m). The resultant bilayer structures apparently remain
closely attached to the interfacial monolayer, as they can readily re-
spread to the monolayer during ﬁlm expansion [4–6,109,110] (Fig. 5).
Molecular dynamic simulations suggest that the bilayer folds remain con-
nected to the lung surfactant monolayer and that the contact area of the
lipid chains with air is reduced by approximately twice the area of the
fold [112]. On the other hand, bilayer reservoirs underlying themonolay-
er, which could also arise from the multilaminations of lamellar bodies,
are believed to play an additional role in stabilizing the interface against
collapse at low surface tensions, especially if bilayers are bridged through
SP-B and SP-C (Fig. 6) [4–6,110]. An important remaining question is how
surfactant ﬁlms with mixed disordered and ordered domains become
enriched in solid-like phase to attainγnear zero duringﬁlm compression.
By combining ToF-SIMS and AFM studies of bovine surfactant ﬁlms at
high π, Keating and co-workers have recently shown that compression-
driven multilayer structures are enriched in unsaturated PLs while the
saturated PLs are concentrated in the remaining interfacial monolayer
[81]. Moreover, they show that multilayers start to form at the edge of
solid-like TC domains and also in the ﬂuid-like LE phase. Fig. 5 shows
how phase coexistence might facilitate ﬁlm folding to form three-
dimensional structures enriched in ﬂuid phase, which would promote
the solidiﬁcation of the interfacial monolayer during exhalation. Hence,
lipid lateral organizationwould aid the ﬁlm to attainminimal surface ten-
sion [80,81].
SP-B and SP-C, which partition preferentially in ﬂuid regions of inter-
facial ﬁlms [89,100–104], seem to facilitate the folding of the surfactant
monolayer induced by compression, resulting in the segregation of un-
saturated phospholipids from the interface. Both SP-B [53,103,104,113]
and SP-C [49,102,111,114–116] promote two- to three-dimensional
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Fig. 5. Dynamic behavior of lung surfactant during respiratory compression-expansion cycling. A) Film compression (exhalation) covers a π range from ~45 to 70 mN/m (γ~23 to
0 mN/m), which represents the physiologically relevant π range. The ability of surfactant to reach very low tensions during exhalation can depend on formation of folded structures,
which start to form at the edge of solid-like TC domains and also in the ﬂuid-like LE phase [81]. The resultant bilayer structures apparently remain closely attached to the interfacial
monolayer, as they can readily re-spread to the monolayer during ﬁlm expansion (B). Folded structures selectively segregate ﬂuid monolayer components [81]. Consequently, after
formation of these protrusions, the interfacial monolayer would be enriched in solid-like domains so that it can reach very low surface tensions. (B) During expansion (inhalation)
surface tension rises to γe (~23 mN/m) by re-spreading of phospholipids into the interface. Folded structures may act as a membrane reserve and attenuate the increase in mem-
brane tension during inspiration.
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dicate that SP-B aggregates (at least dimers) may not only form nucle-
ation sites but bend the monolayer locally and line the highly curved
perimeter of the folds [53]. SP-B has no effect on monolayers forming a
solid-like TC phase. Phase coexistence is required for SP-B-inducedmono-
layer folding [53].
SP-B and SP-C also promote exchange of phospholipids between
membranes [117,118] and between membranes and interfacialFig. 6. Role of surfactant proteins in surfactant dynamics. Surfactant proteins facilitate the op
preferentially in ﬂuid regions of interfacial ﬁlms, seem to facilitate the folding of the surfacta
unsaturated phospholipids from the interface [81]. SP-B has no effect on monolayers formin
ing [53]. In addition, attachment of disconnected bilayers by surfactant proteins constitute
multilayer network in the subphase. The inset shows how SP-B and SP-C promote the estab
factant layers. The palmitoylated cysteines and N-terminal segment of SP-C can insert into m
SP-B, by adopting a bent conformation, binds to the surfaces of both membranes. Finally,
cohesivity between surfactant membranes, which helps to sustain low γ at the end of exhamonolayers [53,119,120]. This suggests that attachment of disconnect-
ed bilayers by surfactant proteins constitutes the ﬁrst step in formation
of a lipid-lined connection between the interface and the multilayer
network in the subphase. Fig. 6 shows how SP-B and SP-C promote
the establishment of membrane–membrane contacts that increase the
cohesivity between surfactant layers. Moreover, the capability of SP-A
to bind simultaneously to different bilayers might increase the cohesivity
between surfactant membranes [5,37]. It is thought that the cohesivity oftimal dynamic behavior of surfactant during breathing. SP-B and SP-C, which partition
nt monolayer induced by compression [53,104,111,116], resulting in the segregation of
g a solid-like TC phase. Phase coexistence is required for SP-B-induced monolayer fold-
s the ﬁrst step in formation of a lipid-lined connection between the interface and the
lishment of membrane–membrane contacts that increase the cohesivity between sur-
embranes or ﬁlms other than that where the hydrophobic α-helix is inserted, whereas
the capability of SP-A to bind simultaneously to different bilayers might increase the
lation [5].
Surfactant+ CRP
-0.8                 GP               +0.8
Surfactant
+ CRP 
GUVs labeled with DiIC18 Laurdan GP
-0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0
Surfactant + CRP
+ CRPDPPC/POPG/PA
Fig. 7. CRP abolishes ordered/disordered phase coexistence and increases ﬂuidity of surfactant membranes. Left, CRP effects on the lipid lateral organization of GUVs prepared from
either porcine lung surfactant or DPPC/POPG/PA (28:9.4:5.1, w/w) doped with the ﬂuorescent probe DiIC18. GUVs composed of surfactant exhibit ﬂuorescent round domains over a
dark background characteristic of liquid-ordered/liquid-disordered (Lo/Ld) phase coexistence, whereas GUVs composed of surfactant-like lipids, which contain no surfactant pro-
teins or cholesterol, show solid/ﬂuid (Lβ′/Lα) phase coexistence. The ﬂuorescent dye is present in the ﬂuid domains and excluded from the micrometer-sized solid domains, which
appear black. The addition of CRP to GUVs composed of lung surfactant or surfactant-like lipids caused disappearance of the Lo/Ld phase coexistence (surfactant) or Lβ′/Lα phase
coexistence (DPPC/POPG/PA) typical of these membranes. Right, top row: two-photon Laurdan GP images of a single surfactant GUV in the absence and presence of 10 wt.%
CRP. Bottom row: Laurdan GP histograms corresponding to the two images presented on top. At 25 °C, the Laurdan GP histogram of surfactant is centred at GP values of ∼0.42.
After CRP addition, the Laurdan GP value decreases to ∼0.14, indicating that CRP ﬂuidizes surfactant membranes.
Adapted from [84].
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halation [4–6].
6. Effect of surfactant inhibitors on ordered/disordered
phase coexistence
Surfactant biophysical activity can be inactivated by incorporation of
materials inhaled from the upper airways, leaked from capillaries, or se-
creted by alveolar cells. Surfactant inhibitors interfere with surfactant
adsorption to the air–liquid interface and prevent surfactant from
reaching low surface tension upon compression and re-spreading dur-
ing expansion [4]. In general it is thought that only some lipids are
capable of inhibiting surfactant functionbymixingwith surfactant com-
ponents and hence altering surfactant structure. These types of inhibi-
tors are lipids that do not form lamellar liquid–crystalline structures
but can be incorporated to some degree in bilayers. These lipids are sol-
uble amphiphilis that form micelles (such as lysophospholipids or bile
acids) or insoluble non-swelling amphiphilis (such as cholesterol,
diacylglycerols, or triacylglycerols). However, recent studies have dem-
onstrated that this mechanism of surfactant inhibition involves some
proteins and particles other than lipids. Here we brieﬂy review the ef-
fects of several surfactant inhibitors that interact with surfactant mem-
branes on both surfactant function and lateral phase separation.
C-reactive protein (CRP) is one of the proteins that have recently
been found to bind to surfactant membranes [84]. CRP inserts into sur-
factant membranes rather than binding to the membrane surface and
affects membrane physical properties. The effect of CRP on surfactant
inactivation is of great interest in lung pathophysiology since CRP dis-
plays a rapid and pronounced increase of concentration in response to
inﬂammation or infection and invades the alveolar space as a result of
increased capillary permeability [121–123]. Fig. 7 shows that insertion
of CRP into surfactant membranes or surfactant-like membranescomposed of DPPC/POPG/palmitic acid (PA) causes disappearance of
micrometer-sized ordered/disordered phase coexistence. In the pres-
ence of CRP, DiIC18 ﬂuorescence is uniform over the GUV surface,
suggesting that ordered domains aremuch smaller than the optical res-
olution of the microscope [84]. Consistent with this morphological in-
formation, Laurdan ﬂuorescence experiments demonstrated that CRP
drastically affects membrane ﬂuidity. Laurdan generalized polarization
images of single GUVs using two-photon excitation ﬂuorescence mi-
croscopy indicate that CRP decreases the Laurdan GP value from 0.4 to
0.1, indicating that CRP has a strong ﬂuidizing effect on these mem-
branes [84]. These alterations in membrane ﬂuidity and lipid lateral or-
ganization correlate with the fact that intratracheal instillation of CRP in
rat lungs causes surfactant inactivation [84]. In addition, CRP hinders
lung surfactant function in vitro: surfactant is unable to reach very low
surface tensions during dynamic ﬁlm compression and to adsorb to an
air–water interface in the presence of CRP [122–126]. Altogether,
these data indicate that CRP-induced alterations in membrane ﬂuidity
and lipid lateral organization correlate with CRP-induced lung surfac-
tant inactivation as demonstrated by in vitro and in vivo studies.
Serum albumin, which also invades the alveolar space in acute
lung injury, has also been shown to affect the structure and function
of surfactant material. Incorporation of albumin molecules into bo-
vine lung surfactant monolayers interferes with their dynamic surface
activity [88,127] and disturbs the characteristic phase coexistence in
bovine lung surfactant ﬁlms, preventing the formation of TC domains
[88]. Albumin also alters the formation of multilayered structures,
which show smaller sizes and single-bilayer thicknesses [88].
Surfactant function is also impaired by cholesterol.While endogenous
levels of cholesterol (about 14–20 mol% or 8–10 wt.% in most mammals
[70]) have no negative effects on surfactant function, supraphysiological
amounts of this sterol have a deleterious effect [4]. Fig. 8 shows how ele-
vated levels of cholesterol (20 wt.%) reduce the ability of surfactant to
10 mol % 15 mol % 18 mol % 21 mol % 30 mol %
Fig. 8. Cholesterol effects on surfactant phase coexistence and function. Top row: ﬂuorescence images of GUVs from the lipid fraction of porcine surfactant, doped with the ﬂuores-
cent probes BODIPY-PC and DiIC18, at different cholesterol/PL molar ratios. GUVs formed from surfactant lipid extract with 10 mol% cholesterol show gel/ﬂuid phase coexistence.
Increasing the cholesterol concentration to 15 mol% induces the appearance of numerous circular-shaped domains characteristic of Lo/Ld phase coexistence. Further increase in cho-
lesterol (up to 30 mol% relative to PL) yields a signiﬁcant increase in the area occupied by Lo phase. Images reproduced from [82] with permission. Bottom row: Dynamic cycles of
bovine lung surfactant in the absence and presence of different amounts of cholesterol. Samples containing less than 20% cholesterol by mass attain near-zero minimum surface
tensions, whereas samples containing 20 wt.% cholesterol only reach surface tensions of 16–20 mN/m.
Adapted from [109] with permission.
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coexistence. In this regard, Bernardino de la Serna and co-workers [82]
showed that increasing the cholesterol mol% in GUVs composed of sur-
factant lipids decreases the area covered by the Ld phase in a dose-
dependent manner (Fig. 8). In surfactant monolayers, supraphysiological
cholesterol levels decrease the area covered by solid-like domains (TC)
[111,129]. In addition, AFM studies of bovine lung surfactant ﬁlms sup-
plemented with 20 wt.% cholesterol indicate that excess cholesterol in-
hibits the monolayer-to-multilayer transition [110,130,133].
In addition, it has been recently demonstrated that meconium im-
pairs pulmonary surfactant by combined action of cholesterol and bile
acids [134]. Micelles of bile acids solubilize cholesterol and facilitate
transfer of this sterol to surfactant complexes. Porcine surfactant ex-
posed to meconium showed higher proportions of condensed-like
phase domains with a strong tendency to aggregate [134]. It is possible
that the probe-excluded domains detected by the authors would corre-
spond to TC and LO phases.
On the other hand, surfactant is also inactivated by incorporation
of materials inhaled from the upper airways. For instance, bacterial li-
popolysaccharide (LPS), the major component of the outer membrane
of Gram negative bacteria, hinders surfactant function. In this regard,
our group has determined that LPS incorporation in porcine lipid ex-
tract surfactant ﬂuidizes surfactant monolayers and hampers surfac-
tant capability to adsorb to a clean air/water interface and to reduce
surface tension to values close to zero (unpublished results). Similar
effects have been observed in ﬁlms of LPS/DPPC mixtures [135,136]
and LPS/surfactant-like lipid mixtures [135]. Both smooth LPS [135]
and deep rough LPS [136] alter LC/LE phase coexistence in DPPC
ﬁlms, decreasing the size and area coverage of TC domains.
Particle inhalation can also impair surfactant function. In this regard,
it has been recently shown that hydroxyapatite nanoparticles (HA-NPs)
alter both the function and lateral structure of modiﬁed natural surfac-
tant ﬁlms [137]. On the one hand, HA-NPs exposure reduces adsorptionand surface tension-lowering properties of the replacement surfactant
Infasurf. On the other hand, HA-NPs decrease the number and size of
condensed domains and alter the monolayer-to-multilayer transition
[137]. Finally, exposure of surfactant to environmental tobacco smoke
(ETS) reduces its surface activity and alters its structure [138]. Surfac-
tant exposed to ETS shows decreased ability to adsorb to the air–
water interface and a reduction in the number and size of condensed
phase domains [138].
Thus there are several surfactant inhibitors that abolish or reduce
ordered/disordered phase coexistence and at the same time interfere
with surfactant biophysical functions. Together, these results suggest
that pulmonary surfactant is one of the membranous systems in
which the coexistence of specialized micrometer-sized membrane
domains is required for its function. Entwining of ordered and disor-
dered domains seems to provide a potential mechanism for mainte-
nance of stable interfacial ﬁlm. A better understanding of surfactant
membrane structure, surfactant susceptibility to inhibition, and po-
tential mechanisms to counteract this inhibition is important for the
development of new therapies for lung immaturity and chronic in-
ﬂammatory lung diseases.
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